We report outcomes for a phase II study of the combination of weekly docetaxel and cisplatin in elderly patients with advanced non-small cell lung cancer. Results: Forty-six (95.8%) of the 48 patients were assessable for response, 1 case of complete response and 18 cases of partial response were confirmed, giving an overall response rate of 39.6% (95% confidence interval ͓CI͔, 25.7-53.5%). The median time to progression and overall survival for all patients was 5.0 months (95% CI, 4
T he incidence of lung cancer in 2007 is estimated to be 213,380 with 160,390 deaths in the United States. It will contribute to 31% of male and 26% of female cancer-related deaths and is the largest cause of cancer-related mortality in both men and women. 1 Forty-two percent of those patients who are newly diagnosed with non-small cell lung cancer (NSCLC) are older than 65 years, and one third to half are older than 70 years. 2, 3 The use of chemotherapy in patients with advanced NSCLC has been shown to improve quality of life, symptom control, median survival, and 1-year survival rates when compared with best supportive care. 4 -7 The use of palliative chemotherapy in the elderly population has been questioned due to the perception that elderly patients may have a higher incidence of comorbidities, and may be less tolerant of the chemotherapy-associated toxicity. This perception has been compounded by the fact that elderly patients are frequently under represented in cooperative group trials, 8 thus, there is limited data in this patient population from which to evaluate the efficacy and toxicity of chemotherapy treatment.
Docetaxel has demonstrated antitumor activity in NSCLC patients with chemotherapy-naive lesions and tumor progression after receiving cisplatin-based regimens. 9 -13 This drug also showed activity as a single agent in untreated elderly advanced NSCLC patients. 14 In the first line setting, docetaxel demonstrated both an interesting activity and efficacy whether combined with a platinum compound. 15 Docetaxel with cisplatin is one of the common chemotherapy regimens for NSCLC. The commonly used dose and schedule of docetaxel is 60 to 100 mg/m 2 every 3 weeks; however, moderate to severe neutropenia is frequently observed. 9 -13,16 Several studies have shown that weekly administration of docetaxel produces a higher dose intensity and less myelo-toxicity. [17] [18] [19] Based on these favorable results, we conducted the present phase II study to evaluate the safety, efficacy, and tolerability of the combination of weekly docetaxel and cisplatin in elderly patients with advanced NSCLC.
PATIENTS AND METHODS

Patient Selection
Patients with histologically and/or cytologically documented NSCLC were eligible for the study. Each patient was required to meet the following criteria: clinical stage IV or IIIB (including only patients with no indications for curative radiotherapy), an Eastern Cooperative Oncology Group performance status (PS) of 0 or 1, age Ն70 years, no prior chemotherapy, measurable lesions, adequate hematological function (white blood cell count 4000 to 12,000/mm 3 ; neutrophils Ն2000/mm 3 ; platelets Ն100,000/mm 3 ; hemoglobin Ն9.0 g/dl), adequate hepatic function (total bilirubin Ͻ1.1 mg/dl, aspartate aminotransferase and alanine aminotransferase Ͻ60 IU/liter), and adequate renal function (creatinine Յ1.2 mg/dl, creatinine clearance Ն60 ml/min). Patients with active infection, severe heart disease, uncontrollable hypertension or diabetes mellitus, active concomitant malignancy and pleural and/or pericardial effusion requiring drainage were excluded. The institutional review board of each author's institution approved the protocol, and written informed consent was obtained from all patients before enrollment.
Patient Evaluation
The pretreatment evaluation consisted of complete blood cell count, differential count, routine chemistry measurements, a chest radiograph, a chest computed tomography (CT) scan, abdominal ultrasound or CT scan, whole-brain magnetic resonance imaging or CT scan, and an isotope bone scan. Complete blood cell count, differential, count and routine chemistry measurements were carried out at least twice a week during the first course of chemotherapy.
Treatment Schedule
All patients were admitted to hospital during the first course of chemotherapy. cisplatin were administered over 15 minutes with 1500 ml normal saline over 3.5 hours. Cisplatin was administered along with a program of forced diuresis that included at least 2000 ml fluids on days 2 to 3.
Dose adjustments at the start of a new cycle were based on the worst toxicity observed during the previous cycle. For hematologic toxicity, subsequent cycles were delayed for up to 2 weeks if grade Ն2 toxicities appeared. The dose of docetaxel was reduced to 80% if grade 4 myelosuppression or febrile neutropenia was present, and if myelosuppression or febrile neutropenia persisted an additional reduction of docetaxel dose to 60% was required. If there was a third such episode docetaxel was discontinued. In the case of grade Ն2 nonhematologic toxicity, treatment was delayed until recovery but not for more than 2 weeks. The dose was reduced in the case of severe nonhematologic toxicity that was not controllable with usual measures, and treatment was discontinued if the patient experienced a significant hypersensitivity reaction or unacceptable toxicity (e.g., grade 4 stomatitis or diarrhea, grade Ն3 peripheral neuropathy, severe and persistent skin/nail changes). Docetaxel administration could be omitted if one of the following toxicities was noted on day 8 or day 15: grade Ն2 hematologic or nonhematologic toxicities, fever Ն38°C, diarrhea of any grade, or a decreased PS. Dose adjustment criteria for cisplatin were based on creatinine clearance, which was calculated before the beginning of each cycle, and neuropathy. The dose of cisplatin could be reduced to 80% for a reversible decrease of creatinine clearance. Cisplatin was also reduced to 80% if grade Ն2 neuropathy appeared.
Chemotherapy was administered for up to six cycles unless there was documented disease progression, unacceptable toxicity, or patient refusal. The prophylactic administration of G-CSF was not permitted. Administration of G-CSF was permitted in patients with grade 4 neutropenia and/or leukopenia or grade 3 febrile neutropenia. Second-line treatments were permitted at the investigators' discretion and the nature of any second-line treatments was recorded.
Response to Treatment and Adverse Effects
After every two cycles of treatment, response was evaluated using RECIST criteria. Of the lesions observed before treatment, a maximum of five measurable lesions from each metastasized organ up to a total of 10 lesions were selected as target lesions. In cases of partial or complete response (CR), a confirmative CT scan was performed 4 weeks later and this was followed by a CT scan after every two treatment cycles. Toxicity was reported using a National Cancer Institute-Common Toxicity Criteria version 2.0 toxicity scale.
Statistical Analysis
The current trial used a two-stage optimal design, as proposed by Simon, 20 with an 80% power to accept the hypothesis and 5% significance to reject the hypothesis. Plus, the current trial was designed to detect a response rate of 40% as compared with a minimal, clinically meaningful response rate of 20%. Allowing for a follow-up loss rate of 10%, the total sample size was 48 patients with a measurable disease. All enrolled patients were included in the intention-to-treat analysis of efficacy. The duration of response, time to progression (TTP), and survival analyses were all estimated using the Kaplan-Meier method. The duration of response was defined as the interval from the onset of a CR or partial response until evidence of disease progression was found. Meanwhile, the TTP was calculated from the initiation of chemotherapy to the date of disease progression, while overall survival was measured from the initiation of chemotherapy to the date of the last follow-up or death. The statistical data were obtained using an SPSS software package (SPSS 11.5 Inc., Chicago, IL).
RESULTS
Patient Characteristics
From June 2004 to July 2006, a total of 48 patients were enrolled in the current study from 5 centers. The characteristics of the patients are summarized in Table 1 . The median age was 76 (range, 70 -86) years, with 30 males and 18 females. Thirty-four (70.8%) patients had a metastatic disease, while 14 patients had a recurrent disease after surgical resection (pulmonary resection) of the primary tumor. Distal lymph nodes and bone were the most common sites of the metastases. No patients had received prior chemotherapy or radiotherapy.
Efficacy and Survival
Forty-six (95.8%) of the 48 patients were assessable for response, of the two patients not assessable, one was lost to follow-up after the first cycle of the treatment, and the other died after the first cycle of unknown cause, although brain metastasis was suspected. All efficacy data are reported using the intent-to-treat patient population. Disease control (objective response and stable disease) in the ITT population was achieved in 83.3% of patients. One case of CR and 18 cases of partial response were confirmed, giving an overall response rate of 39.6% (95% CI, 25.7-53.5%) ( Table 2 ). Of 19 responses, 4 (21.1%) were observed after 3 cycles, 12 (63.2%) after 4 cycles and 3 (15.8%) after 6 cycles. The median follow-up period was 12.4 months. The median TTP for all patients was 5.0 months (95% CI, 4.1-5.7 months) ( Figure 1) . Forty-four patients had died at the time of the present evaluation. The estimated median overall survival was 10.9 months (95% CI, 9.6 -12.2 months) (Figure 2 ).
Toxicity
A total of 148 cycles were administered in 46 patients assessable for toxicity, with a median of 3 cycles per patient (range 1-6 cycles). The occurrence and the incidence of the hematologic and nonhematologic toxicities are shown in Table 3 . The most severe hematologic adverse event was anemia, which occurred with grade 3 intensity in 6 (13.0%) patients and grade 4 in 2 (4.3%) patients. Neutropenia occurred with grade 3 intensity in 4 (8.7%) patients. However, 
Second-Line Treatment
Salvage treatment was not specified in the protocol. Palliative radiotherapy was given to six patients with symptomatic progression in lung, bone, or brain. We offered second-line chemotherapy to 35 patients after failure. Second-line therapy after docetaxel plus cisplatin was mostly nonplatinum therapy: 12 patients received gemcitabine-based therapy, 4 patients received irinotecan, 19 patients were treated with gefitinib or erlotinib. Nine patients received third-line treatment.
DISCUSSION
To date, the optimal regimen for fit, elderly patients is not certain. The present trial, targeting elderly (age 70 years and older) advanced-stage NSCLC patients, was designed to evaluate the safety, efficacy, and tolerability of the combination of weekly docetaxel and cisplatin chemotherapy. In the present trial, the overall response rate according to an intention to treat analysis was 39.6% that was similar to the other previous trials [21] [22] [23] [24] [25] (Table 4) . We observed a median TTP of 5.0 months, a median overall survival of 10.9 months, which can be considered encouraging.
Docetaxel has demonstrated antitumor activity in NSCLC patients with chemotherapy-naive lesions and tumor progression after receiving cisplatin-based regimens. 9 -13 Several recent studies have compared weekly docetaxel to the standard 3-weekly schedule. 26, 27 In a Spanish randomized phase III trial, 26 259 patients from 33 centers were randomized to receive either docetaxel 75 mg/m 2 every 3 weeks or docetaxel 36 mg/m 2 weekly for 6 weeks followed by 2 weeks of rest. Febrile neutropenia was significantly more frequent in the standard treatment arm but more patients in the weekly arm experienced mycosis's. Another randomized phase III study 27 compared a weekly schedule (33.3 mg/m 2 for 6 weeks) to the standard dose (75 mg/m 2 ) in patients Յ75 years of age with an Eastern Cooperative Oncology Group PS Ն2. No difference in the global quality of life scores was found at 3 weeks. Pain, cough, and hair loss were significantly milder with the weekly schedule, while diarrhea was worse. Loss of appetite and overall health were significantly worse in the 3-week arm during the first week, while nausea and loss of appetite were more severe in the weekly arm during the third week. Grade 3-4 hematologic toxicity was significantly more frequent in the standard arm. At higher doses (40 mg/m 2 ) weekly administration remains significantly less toxic with respect to grade 3/4 leukopenia and neutropenia, but druginduced pneumonitis is more frequent. 28, 29 A recent literature-based meta-analysis 30 selected 6 randomized clinical trials (three phase III, 2 phase II, 1018 patients) and confirmed these results, with a significant advantage of weekly docetaxel with respect to grade 3/4 neutropenia (absolute benefit of 15-19%, without a survival improvement). In the 3-week schedule, even with a lower dose (60 mg/m 2 ), grade 3/4 neutropenia remained frequent (86.7% in the study by Takkakaw et al. 31 ). To examine the effects of chemotherapy and Ն65 years enrolled in the multinational, randomized phase II study of TAX 326, found that elderly patients tolerated docetaxel-platinum well despite experiencing slightly more toxicity than younger patients. Hematological and nonhematological toxicities were mild and acceptable in our study. The compliance to treatment was in general good. In particular, the present trial confirms that a modified schedule of docetaxel (20 mg/m 2 ) and cisplatin (25 mg/m 2 ) on days 1, 8, and 15 every 4 weeks is feasible and well tolerated in elderly advanced NSCLC patients. 22 Our tolerability data confirm the previous observations that weekly docetaxel is advantageous in terms of hematological toxicity with respect to 3-weekly schedule. 26, 27, 33, 34 A possible approach to reduce the toxicity of combination regimens consists of administering the same drugs in a sequential manner. This strategy may allow the administration of full dose single agents sequentially without compromising efficacy, while reducing potential toxicity expected with concurrent administration. Preclinical models 35, 36 as well as recent clinical trial in NSCLC suggest a benefit for the sequential administration of chemotherapy agents. We divided the cisplatin and docetaxel dosages on days 1, 8, and 15 because full-dose cisplatin is too toxic for elderly patients. The weekly administration of docetaxel produces a higher dose intensity and less myelotoxicity. [17] [18] [19] 22 Moreover, a weekly schedule may be safer than a 3-weekly schedule because treatment on day 8 and/or day 15 can be omitted if severe toxicity is observed. In the current study, the toxicity, including nausea/vomiting and renal toxicity, was relatively mild, and 92% of the planned administrations were carried out. The dose-limiting toxicities of docetaxel administered in six consecutive weekly infusions were reported to be fatigue and asthenia. [17] [18] [19] However, fatigue and asthenia were relatively mild in our study because of the relatively low-dose of docetaxel (20 mg/m 2 ), similar as the previous study. 22 At the time of beginning of this study, the updated American Society of Clinical Oncology guidelines for the treatment of unrespectable NSCLC was published in January 2004. 37 Recognizing that the optimal duration of chemotherapy remains a matter of debate, Pfizer et al. noted that prolonged chemotherapy can lead to cumulative toxicity, with no proven advantage in efficacy. In fact, the majority of patients failed to have a major response, or became intolerant of chemotherapy, by the third or fourth cycle. Furthermore, in light of new evidence that supports the use of second-line chemotherapy at the time of recurrence, the Panel consensus was to change the prior recommendation, and advocate no more than six cycles of initial chemotherapy, even in patients who have responded to treatment. We conducted this trial of six cycles, even some evidence does not demonstrate any advantage of platinum based chemotherapy after four cycles. 38 In conclusion, the combination of weekly docetaxel and cisplatin is a well-tolerated treatment modality with encouraging activity and survival outcome in previously untreated elderly patients with advanced NSCLC. Whether the combination in this population is superior to the other regimens should be compared in a phase III trial. 
